It activated antigen presentation in DCs, enhanced the priming of tumor antigen-specific CD8 + T cells, improved CD8 + T cell function, and delayed their exhaustion, likely contributing to the robust antitumor response observed with this combination therapy. The gene discussed is CD8A; the disease is neoplasm.